BEKEMV: Uses, Dosage & Side Effects
A complement inhibitor (anti-C5 monoclonal antibody) used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
BEKEMV (eculizumab) is a monoclonal antibody that inhibits the terminal complement pathway by binding to complement protein C5. It is prescribed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired blood disorder causing chronic hemolysis, and atypical hemolytic uremic syndrome (aHUS), a rare condition characterized by complement-mediated thrombotic microangiopathy. BEKEMV is a biosimilar to Soliris and is administered as an intravenous infusion in a hospital setting. Due to the risk of meningococcal infections, patients must be vaccinated before starting treatment.
Quick Facts: BEKEMV
Key Takeaways
- BEKEMV (eculizumab) is a complement C5 inhibitor used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), both rare and potentially life-threatening blood disorders.
- Meningococcal vaccination is mandatory at least 2 weeks before starting treatment, as BEKEMV significantly increases the risk of serious meningococcal infections.
- The medication is given as an intravenous infusion every 1–2 weeks in a hospital setting, with weight-based dosing adjustments for children and adolescents.
- Stopping BEKEMV abruptly can cause a dangerous rebound of symptoms, including severe hemolysis in PNH patients and thrombotic microangiopathy in aHUS patients.
- The most common side effect is headache; the most serious risk is meningococcal infection, which requires immediate medical attention if symptoms such as fever, stiff neck, rash, or confusion develop.
What Is BEKEMV and What Is It Used For?
BEKEMV contains the active substance eculizumab, a humanized monoclonal antibody belonging to the class of complement inhibitors. Eculizumab works by binding to and inhibiting complement protein C5, a key component of the body's innate immune system. By blocking C5, BEKEMV prevents the formation of the membrane attack complex (C5b-9), which is responsible for the destruction of cells in patients with certain rare blood disorders.
The complement system is part of the immune defense that normally helps fight infections and clear damaged cells. However, in some medical conditions, the complement system becomes dysregulated and attacks the body's own healthy cells. BEKEMV provides targeted blockade of this pathway, effectively halting the destructive process while leaving the earlier components of the complement cascade intact for essential immune functions.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
BEKEMV is approved for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematological disorder. In PNH, a genetic mutation in hematopoietic stem cells leads to the production of red blood cells that lack protective surface proteins (GPI-anchored proteins, particularly CD55 and CD59). Without these proteins, the red blood cells become vulnerable to attack and destruction by the complement system, a process known as complement-mediated intravascular hemolysis.
The consequences of uncontrolled hemolysis in PNH can be severe and include chronic anemia (low red blood cell count), fatigue that significantly impairs daily functioning, dark-colored urine (hemoglobinuria, particularly noticeable in the morning), shortness of breath, abdominal pain, difficulty swallowing, and an increased risk of potentially life-threatening blood clots (thrombosis). By blocking C5, BEKEMV prevents the complement system from destroying these vulnerable red blood cells, thereby reducing hemolysis and its associated complications.
Atypical Hemolytic Uremic Syndrome (aHUS)
BEKEMV is also approved for the treatment of adults and children with atypical hemolytic uremic syndrome (aHUS), a rare and serious condition caused by chronic, uncontrolled complement activation. Unlike typical HUS, which is usually triggered by Shiga toxin-producing Escherichia coli (STEC-HUS), aHUS is caused by underlying genetic or acquired abnormalities in complement regulation.
In aHUS, the dysregulated complement system causes inflammation and damage to the small blood vessels (thrombotic microangiopathy, or TMA), particularly in the kidneys. This leads to low platelet counts (thrombocytopenia), destruction of red blood cells as they pass through damaged vessels (microangiopathic hemolytic anemia), and progressive kidney damage that can result in complete renal failure. Other organs, including the brain, heart, and lungs, may also be affected. By inhibiting terminal complement activation, BEKEMV halts the complement-driven process that damages blood vessels and organs in aHUS patients.
BEKEMV is a biosimilar medicine, meaning it is highly similar to another already approved biological medicine (the reference medicine Soliris). Biosimilars undergo rigorous testing to demonstrate that they have no clinically meaningful differences from the reference product in terms of quality, safety, and efficacy. BEKEMV offers the same therapeutic benefits as the originator eculizumab product.
What Should You Know Before Taking BEKEMV?
Contraindications
BEKEMV must not be used in the following situations:
- Allergy to eculizumab or any other ingredient in BEKEMV (see the Contents section for a full list of excipients).
- Hereditary fructose intolerance, a rare inherited condition in which the enzyme that breaks down fructose is not produced. BEKEMV contains sorbitol, which is a source of fructose.
- Children under 2 years of age with suspected hereditary fructose intolerance, as the diagnosis may not yet have been confirmed in this age group.
- Unvaccinated patients who have not received meningococcal vaccination, unless they are taking prophylactic antibiotics to reduce the risk of infection until at least 2 weeks after vaccination.
- Active meningococcal infection at the time of treatment initiation.
Warnings and Precautions
Treatment with BEKEMV significantly impairs your natural defense against Neisseria meningitidis infections (meningococcal disease), including meningitis and sepsis. These infections can be rapidly fatal if not recognized and treated immediately. You will receive a patient safety card listing the warning symptoms that you should carry at all times during treatment.
Before starting BEKEMV, your doctor will ensure that you are vaccinated against Neisseria meningitidis (meningococcal disease) at least 2 weeks before treatment begins. If urgent treatment is needed before the 2-week post-vaccination period has elapsed, your doctor will prescribe prophylactic antibiotics to cover this period. Your meningococcal vaccination should be kept up to date according to current medical guidelines, and your doctor may recommend additional protective measures based on national recommendations.
Seek immediate medical attention if you experience any of the following symptoms during or after BEKEMV treatment, as they may indicate a meningococcal infection:
- Headache with nausea or vomiting
- Headache with stiffness in the neck or back
- Fever
- Skin rash (particularly a non-blanching rash)
- Confusion or altered mental status
- Severe muscle pain combined with flu-like symptoms
- Sensitivity to light (photophobia)
If you are traveling to remote areas where medical care may not be readily available, your doctor may prescribe a course of antibiotics effective against Neisseria meningitidis for you to carry. If you experience any of the symptoms listed above while traveling, take the antibiotics as directed and seek medical care as soon as possible, even if you feel better after taking them.
BEKEMV treatment may also increase the risk of other Neisseria infections, including disseminated gonococcal infection. If you are at risk for gonorrhea, consult your doctor before starting treatment.
Children and adolescents under 18 years of age must also be vaccinated against Haemophilus influenzae type b and pneumococcal infections in accordance with national immunization recommendations for their age group.
Before starting BEKEMV, inform your doctor if you have any current infections. Because BEKEMV is a protein-based medicine, allergic reactions are possible in some individuals. Report any previous history of drug allergies to your treating physician.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before using BEKEMV. There is limited clinical data on the use of eculizumab during pregnancy. As a human IgG antibody, eculizumab is expected to cross the placenta, particularly during the second and third trimesters.
Women of childbearing potential should consider using effective contraception during treatment and for at least 5 months after the last dose of BEKEMV. The decision to use BEKEMV during pregnancy or breastfeeding should be made in consultation with your physician, who will carefully weigh the potential benefits against the possible risks.
Elderly Patients
No special dose adjustments or precautions are required for patients aged 65 years and older. The safety and efficacy profile of BEKEMV in elderly patients is consistent with that observed in the general adult population.
Driving and Operating Machinery
BEKEMV has no or negligible effect on the ability to drive and use machines. You may continue your normal activities in this regard.
Important Information About Excipients
Sorbitol: BEKEMV contains 50 mg of sorbitol per ml. Sorbitol is a source of fructose. If you or your child has hereditary fructose intolerance, you must not use this medicine. Contact your doctor if your child can no longer tolerate sweet food or drinks, or experiences nausea, vomiting, bloating, stomach cramps, or diarrhea after consuming them.
Sodium: When diluted with 0.9% sodium chloride solution, BEKEMV at the highest dose contains up to 0.34 g of sodium per dose, equivalent to approximately 17% of the WHO recommended maximum daily sodium intake for adults. This should be considered if you are on a sodium-restricted diet. If diluted with 5% glucose, the medicine is essentially sodium-free.
Polysorbate 80: BEKEMV contains 3.0 mg of polysorbate 80 (E433) per vial. Polysorbates may cause allergic reactions in some individuals. Inform your doctor if you have any known allergies to polysorbates.
How Does BEKEMV Interact with Other Drugs?
Unlike many small-molecule drugs, BEKEMV (eculizumab) is a monoclonal antibody and is not metabolized through the cytochrome P450 (CYP) enzyme system. Therefore, it has minimal potential for traditional pharmacokinetic drug-drug interactions. However, there are several important clinical considerations regarding concomitant therapies.
| Interacting Drug/Procedure | Effect | Clinical Recommendation |
|---|---|---|
| Plasma exchange / Plasmapheresis | Removes eculizumab from the bloodstream, potentially reducing complement blockade below therapeutic levels | Supplemental doses of BEKEMV may be required after plasma exchange sessions. Consult your treating physician for dosing guidance. |
| Intravenous immunoglobulin (IVIg) | May interfere with the recycling of eculizumab through the neonatal Fc receptor (FcRn), potentially reducing drug exposure | Monitor complement activity and clinical response when IVIg is administered concurrently. Dose adjustments may be necessary. |
| Other eculizumab products (Soliris, Epysqli) | Concurrent use with other eculizumab-containing products would result in overdosing without additional therapeutic benefit | Do not use BEKEMV concurrently with other eculizumab biosimilars or the reference product. Switching between products should be done under medical supervision. |
| Meningococcal vaccines | Required co-administration to reduce the risk of meningococcal infection during complement inhibition | Must be administered at least 2 weeks before starting BEKEMV. Keep vaccinations up to date throughout treatment. |
| Anticoagulants (e.g., warfarin, heparin) | No direct pharmacokinetic interaction, but discontinuation of BEKEMV in PNH patients may increase thrombotic risk | Anticoagulation management should be reviewed if BEKEMV is discontinued, particularly in PNH patients with a history of thrombosis. |
Always inform your doctor, pharmacist, or nurse about all medicines you are currently using, have recently used, or might use. This includes over-the-counter medications, herbal products, and nutritional supplements. While significant interactions are uncommon with monoclonal antibodies, a complete medication review ensures the safest possible treatment plan.
What Is the Correct Dosage of BEKEMV?
BEKEMV is always administered by a healthcare professional as an intravenous (IV) infusion (drip). It must never be given as an intravenous push or bolus injection. Before the first dose, your doctor will ensure you have received meningococcal vaccination at least 2 weeks prior, or will prescribe prophylactic antibiotics if vaccination was more recent.
Adults with PNH
Induction Phase (Weeks 1–4)
Dose: 600 mg intravenously once weekly for 4 consecutive weeks
Infusion duration: Approximately 25–45 minutes (35 minutes ± 10 minutes)
Maintenance Phase (Week 5 onward)
Dose: 900 mg intravenously at week 5, then 900 mg every 2 weeks as ongoing long-term treatment
Infusion duration: Approximately 25–45 minutes (35 minutes ± 10 minutes)
Adults with aHUS
Induction Phase (Weeks 1–4)
Dose: 900 mg intravenously once weekly for 4 consecutive weeks
Infusion duration: Approximately 25–45 minutes (35 minutes ± 10 minutes)
Maintenance Phase (Week 5 onward)
Dose: 1,200 mg intravenously at week 5, then 1,200 mg every 2 weeks as ongoing long-term treatment
Infusion duration: Approximately 25–45 minutes (35 minutes ± 10 minutes)
Children and Adolescents
Children and adolescents weighing 40 kg or more receive the same dose as adults for both PNH and aHUS. Children weighing less than 40 kg receive weight-based dosing as described below.
| Body Weight | Induction Phase | Maintenance Phase |
|---|---|---|
| 30 to < 40 kg | 600 mg weekly for 2 weeks | 900 mg at week 3, then 900 mg every 2 weeks |
| 20 to < 30 kg | 600 mg weekly for 2 weeks | 600 mg at week 3, then 600 mg every 2 weeks |
| 10 to < 20 kg | 600 mg single dose at week 1 | 300 mg at week 2, then 300 mg every 2 weeks |
| 5 to < 10 kg | 300 mg single dose at week 1 | 300 mg at week 2, then 300 mg every 3 weeks |
Patients who undergo plasma exchange or plasmapheresis may require supplemental doses of BEKEMV, as these procedures can remove the drug from the bloodstream. Your doctor will determine whether additional dosing is needed based on your clinical response and complement activity levels.
Monitoring During Infusion
After each infusion, you will be monitored for approximately one hour for any signs of infusion-related reactions or adverse effects. If a reaction occurs during the infusion, the healthcare team may slow the infusion rate or stop it entirely. If the infusion rate is reduced, the total infusion time should not exceed 2 hours in adults or 4 hours in pediatric patients under 18 years of age.
Missed Dose
If you miss a scheduled infusion, contact your doctor or treatment center immediately to arrange a replacement appointment. Maintaining the regular dosing schedule is essential for keeping complement activity adequately suppressed. A missed dose can lead to a return of complement-mediated disease activity.
Overdose
If you suspect you have received a higher dose of BEKEMV than recommended, contact your doctor for advice. There is no specific antidote for eculizumab overdose. Treatment would be supportive and based on clinical symptoms.
Stopping Treatment
Discontinuing BEKEMV can cause a dangerous rebound of disease activity. In PNH patients, this may include severe hemolysis, significant anemia, confusion, chest pain, kidney problems, and blood clots. In aHUS patients, discontinuation may trigger a recurrence of thrombotic microangiopathy with low platelet counts, kidney failure, and blood clots. Your doctor will monitor you closely for at least 8 weeks after stopping treatment.
What Are the Side Effects of BEKEMV?
Like all medicines, BEKEMV can cause side effects, although not everyone experiences them. Most side effects are mild to moderate in severity. Your doctor will discuss the potential benefits and risks of BEKEMV with you before starting treatment. The most serious side effect associated with BEKEMV treatment is meningococcal sepsis — contact your doctor immediately if you develop any symptoms of meningococcal infection (see the Warnings section above).
Very Common
May affect more than 1 in 10 people
- Headache
Common
May affect up to 1 in 10 people
- Pneumonia, common cold (nasopharyngitis), urinary tract infection
- Low white blood cell count (leukopenia), decreased red blood cells causing pallor, weakness, and shortness of breath
- Insomnia (inability to sleep)
- Dizziness, high blood pressure
- Upper respiratory tract infection, cough, sore throat, bronchitis, cold sores (herpes simplex)
- Diarrhea, vomiting, nausea, abdominal pain
- Skin rash, hair loss (alopecia), itching (pruritus)
- Joint pain (arthralgia), pain in the arms and legs
- Fever, fatigue, flu-like illness
- Infusion-related reaction
Uncommon
May affect up to 1 in 100 people
- Serious infection (meningococcal infection), sepsis, septic shock, viral infection, lower respiratory tract infection, gastroenteritis, cystitis
- Infection, fungal infection, abscess, skin infection (cellulitis), influenza, sinusitis, tooth abscess, gum infection
- Low platelet count (thrombocytopenia), low lymphocyte count (lymphopenia), palpitations
- Serious allergic reaction (anaphylaxis), hypersensitivity
- Loss of appetite, depression, anxiety, mood swings, sleep disturbance
- Tingling in parts of the body (paresthesia), tremor, taste disturbance, fainting (syncope)
- Blurred vision, tinnitus (ringing in the ears), vertigo
- Sudden and rapid development of extremely high blood pressure, low blood pressure, hot flushes, vascular disorders
- Difficulty breathing (dyspnea), nosebleed, nasal congestion, throat irritation, runny nose
- Peritonitis, constipation, indigestion (dyspepsia), abdominal distension
- Elevated liver enzymes, urticaria (hives), redness, dry skin, red or purple spots under the skin, increased sweating, skin inflammation
- Muscle cramps, muscle pain, back and neck pain, bone pain
- Kidney disease, difficulty or pain during urination, blood in the urine
- Spontaneous erection
- Swelling (edema), chest discomfort, weakness (asthenia), chest pain, pain at infusion site, chills
Rare
May affect up to 1 in 1,000 people
- Aspergillus infection, bacterial joint infection (septic arthritis), Haemophilus infection, impetigo, gonorrhea
- Skin tumor (melanoma), bone marrow disorder
- Decreased red blood cell count, abnormal blood clotting factor, abnormal blood coagulation
- Overactive thyroid disease (Graves' disease)
- Abnormal dreams, eye irritation, bruising
- Acid reflux, gum pain, jaundice (yellowing of skin and eyes)
- Skin discoloration, facial muscle spasm, joint swelling
- Menstrual irregularities
- Abnormal leakage of infusion drug from the vein, unusual sensation at the infusion site, feeling of warmth
Not Known
Frequency cannot be estimated from available data
- Liver damage (hepatotoxicity)
If you experience any side effects, including possible side effects not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national health authority or medicines regulatory agency. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store BEKEMV?
Proper storage of BEKEMV is essential to maintain its effectiveness and safety. The following storage conditions must be observed:
- Temperature: Store in a refrigerator at 2°C–8°C (36°F–46°F). Do not freeze. Do not use BEKEMV if it has been frozen.
- Light protection: Keep the vials in their original carton to protect from light.
- Room temperature excursion: BEKEMV vials in the original packaging may be removed from the refrigerator for a single period of up to 7 days at room temperature. At the end of this period, the product may be returned to the refrigerator.
- After dilution: The diluted solution should be used within 24 hours. Diluted solutions may be stored at 2°C–8°C prior to administration.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and vial label after "EXP." The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help protect the environment.
Keep this medicine out of the sight and reach of children at all times.
What Does BEKEMV Contain?
The active substance is eculizumab, present at a concentration of 10 mg/ml. Each vial contains 300 mg of eculizumab in 30 ml of solution.
The inactive ingredients (excipients) are:
- Acetic acid
- Sodium hydroxide (E524)
- Ethylenediaminetetraacetic acid (EDTA)
- Sorbitol (E420)
- Polysorbate 80 (E433, of vegetable origin)
- Water for injections
Appearance and Packaging
BEKEMV is a concentrate for solution for infusion. It is a clear to opalescent, colorless to slightly yellow solution. Each carton contains 1 vial of 30 ml.
Preparation and Administration (Healthcare Professionals)
BEKEMV must be prepared and administered by qualified healthcare professionals using aseptic technique. The required dose is withdrawn from the vial(s) using a sterile syringe and diluted to a final concentration of 5 mg/ml using an appropriate diluent (0.9% sodium chloride, 0.45% sodium chloride, or 5% glucose in water). The diluted solution is administered by intravenous infusion over 25–45 minutes in adults, or 1–4 hours in pediatric patients under 18 years. The diluted solution does not need to be protected from light during administration.
Marketing Authorization
Marketing Authorization Holder: Amgen Technology (Ireland) UC, Pottery Road, Dun Laoghaire, Co. Dublin, A96 F2A8, Ireland.
Manufacturer: Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, Netherlands.
Additional information about this medicine is available on the European Medicines Agency website.
Frequently Asked Questions About BEKEMV
BEKEMV is a biosimilar of Soliris. Both contain the same active ingredient (eculizumab) and work in the same way by blocking complement protein C5. Biosimilars undergo extensive comparative testing to demonstrate that they have no clinically meaningful differences from the reference product in terms of quality, safety, and efficacy. BEKEMV is manufactured by Amgen, while Soliris is manufactured by Alexion (AstraZeneca). Your doctor may choose BEKEMV based on availability and healthcare system considerations, and you can expect the same therapeutic outcomes as with Soliris.
BEKEMV is typically a long-term treatment. For PNH, treatment is usually continued indefinitely, as the underlying condition is chronic and symptoms will return if complement inhibition is stopped. For aHUS, the duration of treatment is determined by your doctor based on the underlying cause, clinical response, and individual risk factors. Some aHUS patients may be able to discontinue treatment under careful medical supervision, though this carries a risk of disease relapse. Never stop BEKEMV without consulting your doctor.
BEKEMV does not cure PNH or aHUS, but it effectively controls the symptoms and prevents the most serious complications of these conditions. In PNH, it reduces hemolysis (destruction of red blood cells), improves anemia, and lowers the risk of blood clots. In aHUS, it stops complement-mediated damage to blood vessels and kidneys. Clinical trials have shown significant and sustained improvements in quality of life for patients treated with eculizumab. However, stopping treatment may cause the disease to flare, so ongoing treatment is generally necessary.
Before starting BEKEMV, you must receive a meningococcal (Neisseria meningitidis) vaccine at least 2 weeks before the first dose. Both conjugate and serogroup B vaccines are typically recommended to provide the broadest protection. If urgent treatment is needed before the 2-week vaccination window, your doctor will prescribe prophylactic antibiotics. Children and adolescents under 18 also need to be vaccinated against Haemophilus influenzae type b and pneumococcal infections according to national guidelines. Your doctor will ensure all necessary vaccinations are up to date before initiating treatment.
There is limited clinical data on the use of BEKEMV during pregnancy. As a human IgG monoclonal antibody, eculizumab is expected to cross the placenta, particularly in the second and third trimesters. However, for women with PNH or aHUS, pregnancy itself can be a high-risk period with increased disease activity. The decision to use BEKEMV during pregnancy must be made carefully by the treating specialist, weighing the potential risks to the developing baby against the serious health risks of untreated PNH or aHUS during pregnancy. Effective contraception should be used during treatment and for 5 months after the last dose.
If you experience any symptoms that could indicate meningococcal infection — including sudden headache with nausea/vomiting, headache with stiff neck, high fever, a rash (especially one that does not fade when pressed), confusion, severe muscle pain with flu-like symptoms, or sensitivity to light — you should seek emergency medical attention immediately. Meningococcal infection can progress rapidly and can be fatal within hours if untreated. Always carry your patient safety card, which lists these symptoms, and show it to any healthcare professional treating you. If you are traveling in remote areas, take the emergency antibiotics your doctor has prescribed and seek medical care as soon as possible.
References
- European Medicines Agency (EMA). BEKEMV (eculizumab) – Summary of Product Characteristics. European Medicines Agency, 2025.
- U.S. Food and Drug Administration (FDA). Soliris (eculizumab) – Prescribing Information. U.S. FDA, 2024.
- Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine. 2006;355(12):1233–1243.
- Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847.
- Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New England Journal of Medicine. 2013;368(23):2169–2181.
- Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology. 2012;8(11):643–657.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Glomerulonephritis. KDIGO, 2024.
- Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Seminars in Immunology. 2016;28(3):223–240.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd edition. WHO, 2023.
- Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program. 2016;2016(1):208–216.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with expertise in hematology, nephrology, clinical pharmacology, and rare diseases. All content follows international clinical guidelines and is based on peer-reviewed evidence.
Medical Content
iMedic Hematology & Rare Disease Editorial Team — specialists in complement-mediated disorders and biologic therapies
Medical Review
iMedic Medical Review Board — independent panel of physicians who verify accuracy according to EMA, FDA, and WHO guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team — specialists in drug safety, interactions, and monoclonal antibody therapeutics
Accessibility Review
iMedic Accessibility Team — ensuring WCAG 2.2 AAA compliance and readability for all users, including those using assistive technology
Evidence Standard: All medical claims in this article are supported by Level 1A evidence (systematic reviews and randomized controlled trials) where available, following the GRADE evidence framework. Sources include EMA SmPC, FDA prescribing information, peer-reviewed journals, and WHO guidelines.
Conflict of Interest: iMedic receives no funding from pharmaceutical companies. This content is entirely independent and evidence-based.